WHO Recommends Two New Ebola Vaccine Candidates for Clinical Trial in DRC

Expert groups convened by the World Health Organization (WHO) have recommended adding two new Ebola vaccine candidates, ChAdOx1 (developed by the University of Oxford with the Serum Institute of India) and Moderna's mRNA-1469, to the ongoing Tumaini clinical trial in the Democratic Republic of the Congo (DRC). This marks the first time vaccines specifically designed to protect against the Bundibugyo virus, responsible for the current outbreak, will be evaluated during an outbreak.